A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
Study Details
Study Description
Brief Summary
The study objectives are to evaluate the safety of a single intravenous (IV) infusion of autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria in participant with primary mitochondrial disease associated with mitochondrial DNA mutations or deletions.
6 participants aged from 4 to 18 years old on the day of screening visit with primary mitochondrial disease associated with mitochondrial DNA mutations or deletions will be enrolled.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
MNV-BM-PLC is a personalized cell therapy based on autologous patient-derived Hematopoietic stem/progenitor cells (HSPCs) enriched with mitochondria isolated from healthy placenta obtained from donors during C-section. Healthy mitochondria are employed, ex-vivo, to enrich the patient's CD34+ peripheral blood cells, followed by infusion of the mitochondrial enriched cells back to the patient. This therapeutic process of mitochondrial augmentation provides the patient with healthy mitochondria carrying non-mutated/deleted mtDNA that can supplement mitochondrial functionality in the patient's cells.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Cohort 1 & Cohort 2 3 patients will be administrated with Dose 1 (0.88 mitochondria unit (mU) citrate synthase (CS) activity per million cells). 3 patients will be administrated with Dose 2 (4.4mU mitochondria unit (mU) citrate synthase (CS) activity per million cells). |
Procedure: Bone Marrow mobilization
During four days before the apheresis, Neupogen (G-CSF) at a dose of 10 microgram per kilogram will be administered subcutaneously in the morning (days -6 to -3 of cell therapy). In addition, Mozobil (Plerixafor) at a dose of 0.24 milligram per kilogram will be administered subcutaneously approximately 4 hours before apheresis initiation.
A fifth dose of Neupogen (G-CSF) will be administered just prior to the apheresis
Procedure: Apheresis
Apheresis will be performed two days prior to MNV-BM-PLC infusion. During this procedure, patient's peripheral blood will be collected by apheresis
Biological: MNV-BM-PLC infusion
The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.
The dosing interval between patients will be at minimum 2 weeks.
|
Outcome Measures
Primary Outcome Measures
- Number of participants with Treatment-related adverse events as assessed by CTCAE v5.0 following MNV-BM-PLC [1 month]
Severity will graded according to CTCAE, Version 5.0
- Measurement of hemoglobin level [1 month]
Change from baseline in hematological parameter
- Measurement of absolute neutrophil count [1 month]
Change from baseline in hematological parameter
- Measurement of platelet count [1 month]
Change from baseline in hematological parameter
Secondary Outcome Measures
- Number of participants with Treatment-related adverse events as assessed by CTCAE v5.0 following MNV-BM-PLC [2 years]
Severity will graded according to CTCAE, Version 5.0
- Measurement of hemoglobin level [2 years]
Change from baseline in hematological parameter
- Measurement of absolute neutrophil count [2 years]
Change from baseline in hematological parameter
- Measurement of platelet count [2 years]
Change from baseline in hematological parameter
- IPMDS (International Pediatric Mitochondrial Disease Scale) [2 years]
To compare the change in International Pediatric Mitochondrial Disease Scale (IPMDS) score during a follow up period of 3, 6 12 and 24 months post treatment. IPMDS total score ranges from 0 to 243. The score is expressed as the percentage of items which were feasible to perform. The lower the score is, the higher the child's function
- Performance Score [2 years]
Stabilization or improvement in performance score (Lansky score (for patients younger than 15 years) or Karnofsky (for patients older than 15) score relative to baseline
- PEDI: Pediatric Evaluation of Disability Inventory [2 years]
Stabilization or improvement in PEDI score relative to baseline
- 6-minute walk test [2 years]
Stabilization or improvement in 6-minute walk test relative to baseline
- 30 Second chair stand [2 years]
Stabilization or improvement in 30 Second chair stand relative to baseline
- Hospitalization events [1 year]
Reduction in number, cause and duration of hospitalization events relative to 12 months before IP treatment
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Molecular diagnosis of primary mitochondrial disease
-
Age between 4 years and up to 18 years, with a minimum body weight of 20 (+/-1) kilogram on the day of screening visit.
-
Performance score: Karnofsky ≥40 (or equivalent in children younger than 16 years old.
-
Patients or Patient's parents or legal guardian (where applicable) has a good understanding of the study and nature of the procedure and is willing and able to provide written informed consent prior to participation in any study-related procedures.
-
Medical ability to undergo the study procedures safely, as determined by the investigator.
Exclusion Criteria
-
Positive test for pathogenic agents .
-
Inability to undergo leukapheresis, as determined by the investigator.
-
Chronic severe infection or any other disease or condition that may risk the patient or interfere with the ability to interpret the study results.
-
Known history of malignancy.
-
Patient has been treated within the last one year prior to IP treatment with a different cell therapy.
-
Patient has participated in another interventional clinical study and/or received other experimental medication outside of a clinical study within 1 month prior the day of Investigation product (IP) treatment visit.
-
A pregnant or lactating woman or a woman who plans to become pregnant during the study. In addition, any woman of childbearing potential (not sterile or postmenopausal), who is unwilling to adhere to the use highly effective contraception method for the duration of the study
-
In the opinion of the Investigator, the patient is unsuitable for participating in the study due to safety concerns.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sheba Medical Center - Tel Ashomer | Ramat Gan | Israel |
Sponsors and Collaborators
- Minovia Therapeutics Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PLC-PMD-01-IL